CN104945471A - 贻贝蛋白降压肽 - Google Patents
贻贝蛋白降压肽 Download PDFInfo
- Publication number
- CN104945471A CN104945471A CN201510177322.8A CN201510177322A CN104945471A CN 104945471 A CN104945471 A CN 104945471A CN 201510177322 A CN201510177322 A CN 201510177322A CN 104945471 A CN104945471 A CN 104945471A
- Authority
- CN
- China
- Prior art keywords
- trp
- ace
- magnetic microsphere
- solution
- antihypertensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 36
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 32
- 241000237536 Mytilus edulis Species 0.000 title claims abstract description 29
- 235000020638 mussel Nutrition 0.000 title claims abstract description 29
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims abstract description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 29
- 235000018102 proteins Nutrition 0.000 claims description 16
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 abstract description 37
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 abstract description 37
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 abstract description 37
- 239000004005 microsphere Substances 0.000 abstract description 35
- 229920000936 Agarose Polymers 0.000 abstract description 30
- 238000000108 ultra-filtration Methods 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 12
- 238000004007 reversed phase HPLC Methods 0.000 abstract description 12
- 235000013372 meat Nutrition 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 238000005377 adsorption chromatography Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 230000000694 effects Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011259 mixed solution Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 2
- LRWZZZWJMFNZIK-UHFFFAOYSA-N 2-chloro-3-methyloxirane Chemical compound CC1OC1Cl LRWZZZWJMFNZIK-UHFFFAOYSA-N 0.000 description 2
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 2
- 102400000967 Bradykinin Human genes 0.000 description 2
- 101800004538 Bradykinin Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 241000237524 Mytilus Species 0.000 description 2
- 241000143233 Mytilus coruscus Species 0.000 description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229950007884 alacepril Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 229960002490 fosinopril Drugs 0.000 description 2
- 239000007986 glycine-NaOH buffer Substances 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- 239000011553 magnetic fluid Substances 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- AIZVVCMAFRREQS-GUBZILKMSA-N Pro-Cys-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AIZVVCMAFRREQS-GUBZILKMSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- SDHZOOIGIUEPDY-JYJNAYRXSA-N Val-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 SDHZOOIGIUEPDY-JYJNAYRXSA-N 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 108010084932 tryptophyl-proline Proteins 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510177322.8A CN104945471B (zh) | 2015-04-15 | 2015-04-15 | 贻贝蛋白降压肽 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510177322.8A CN104945471B (zh) | 2015-04-15 | 2015-04-15 | 贻贝蛋白降压肽 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104945471A true CN104945471A (zh) | 2015-09-30 |
CN104945471B CN104945471B (zh) | 2020-09-08 |
Family
ID=54160586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510177322.8A Active CN104945471B (zh) | 2015-04-15 | 2015-04-15 | 贻贝蛋白降压肽 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104945471B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106928332A (zh) * | 2017-01-10 | 2017-07-07 | 大连工业大学 | 一种不同溶解性的贻贝蛋白及多肽的制备方法 |
CN112135619A (zh) * | 2018-03-27 | 2020-12-25 | 三福有限公司 | 生物活性青口贝提取物及其用途 |
CN114044807A (zh) * | 2021-11-19 | 2022-02-15 | 浙江海洋大学 | 一种治疗高脂血症的贻贝降血脂寡肽 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948899A (zh) * | 2010-09-16 | 2011-01-19 | 浙江工商大学 | 酶解贻贝蛋白制备降血压肽的方法 |
CN103204906A (zh) * | 2013-01-29 | 2013-07-17 | 浙江海洋学院 | 一种贻贝肉蛋白抗氧化肽及其制备方法 |
-
2015
- 2015-04-15 CN CN201510177322.8A patent/CN104945471B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101948899A (zh) * | 2010-09-16 | 2011-01-19 | 浙江工商大学 | 酶解贻贝蛋白制备降血压肽的方法 |
CN103204906A (zh) * | 2013-01-29 | 2013-07-17 | 浙江海洋学院 | 一种贻贝肉蛋白抗氧化肽及其制备方法 |
Non-Patent Citations (2)
Title |
---|
毋瑾超等: "贻贝蛋白酶解降血压肽的降压活性及相对分子质量与氨基酸组成", 《水产学报》 * |
毋瑾超等: "贻贝酶解降压肽的降压活性及其安全性评价", 《天然产物研究与开发》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106928332A (zh) * | 2017-01-10 | 2017-07-07 | 大连工业大学 | 一种不同溶解性的贻贝蛋白及多肽的制备方法 |
CN112135619A (zh) * | 2018-03-27 | 2020-12-25 | 三福有限公司 | 生物活性青口贝提取物及其用途 |
JP2021519304A (ja) * | 2018-03-27 | 2021-08-10 | サンフォード リミテッド | 生理活性ミドリイガイ抽出物及びその使用 |
CN114044807A (zh) * | 2021-11-19 | 2022-02-15 | 浙江海洋大学 | 一种治疗高脂血症的贻贝降血脂寡肽 |
CN114044807B (zh) * | 2021-11-19 | 2023-08-22 | 浙江海洋大学 | 一种治疗高脂血症的贻贝降血脂寡肽 |
Also Published As
Publication number | Publication date |
---|---|
CN104945471B (zh) | 2020-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104762358A (zh) | 贻贝蛋白降压肽的快速制备方法 | |
CN103052717B (zh) | 一种工业化生产玉米降压活性肽的方法 | |
CN105111282B (zh) | 一种具有ace抑制活性的核桃肽及其制备方法 | |
CN102808010A (zh) | 一种酶解金枪鱼碎肉蛋白制备降压肽的方法 | |
CN103923177B (zh) | 一种海洋微藻来源的血管紧张素转化酶抑制肽 | |
CN103980347A (zh) | 一种大黄鱼鱼鳔降压肽及其制备方法和用途 | |
CN104774896A (zh) | 带鱼鱼骨铁螯合胶原肽制备方法 | |
CN101906135A (zh) | 一种新型螺旋藻源降血压肽及其制备方法 | |
CN104945471A (zh) | 贻贝蛋白降压肽 | |
CN108484723A (zh) | 浒苔来源的血管紧张素转化酶抑制肽及其制备方法和应用 | |
WO2020014997A1 (zh) | 高f值寡肽及其制备方法 | |
CN104131055B (zh) | 一种藻红蛋白ace抑制肽的制备方法 | |
CN104757561A (zh) | 一种贻贝蛋白降压肽的用途 | |
CN113943346A (zh) | 螺旋藻降压肽及应用 | |
US20150183822A1 (en) | Angiotensin-converting-enzyme inhibiting dipeptide | |
CN101830967A (zh) | 一种具有血管紧张素转移酶抑制活性的寡肽及其制备方法 | |
CN104945501A (zh) | 一种带鱼鱼骨铁螯合胶原肽 | |
CN113072621B (zh) | 一种牦牛骨降血压肽及其制备方法与应用 | |
CN109369781A (zh) | 一种麒麟菜抗氧化四肽及其应用 | |
CN116120431A (zh) | 一种抗氧化胶原多肽、制备方法及其应用 | |
CN102199192A (zh) | 一种从龟甲胶中分离功能多肽的方法 | |
CN108048518A (zh) | 鸡血球抗氧化肽及其酶解制备方法 | |
JP2007297324A (ja) | ペプチド及びその製造方法、並びにアンジオテンシン変換酵素阻害剤 | |
CN102887940A (zh) | 来源于贝类加工副产物的生物活性肽及其制备方法 | |
JP2007297325A (ja) | ペプチド及びその製造方法、並びにアンジオテンシン変換酵素阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201209 Address after: 235000 north side of Qifeng road xifengguan Road, Xiangshan District, Huaibei City, Anhui Province Patentee after: ANHUI SHENGMEINUO BIOLOGY TECHNOLOGY Co.,Ltd. Address before: 316022 No. 1, Haida South Road, Changzhi Island, Lincheng street, Zhoushan, Zhejiang. Patentee before: ZHEJIANG OCEAN University |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Yibei protein antihypertensive peptide Granted publication date: 20200908 Pledgee: Huaibei Rural Commercial Bank Co.,Ltd. science and technology sub branch Pledgor: ANHUI SHENGMEINUO BIOLOGY TECHNOLOGY Co.,Ltd. Registration number: Y2024980021824 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |